1.42
+0.15(+11.81%)
Currency In USD
| Previous Close | 1.27 |
| Open | 1.3 |
| Day High | 1.42 |
| Day Low | 1.28 |
| 52-Week High | 5.95 |
| 52-Week Low | 0.81 |
| Volume | 498,966 |
| Average Volume | 305,784.1 |
| Market Cap | 15.33M |
| PE | -1.21 |
| EPS | -1.17 |
| Moving Average 50 Days | 1.01 |
| Moving Average 200 Days | 1.23 |
| Change | 0.15 |
If you invested $1000 in Marker Therapeutics, Inc. (MRKR) 10 years ago, it would be worth $15.99 as of December 04, 2025 at a share price of $1.42. Whereas If you bought $1000 worth of Marker Therapeutics, Inc. (MRKR) shares 5 years ago, it would be worth $83.53 as of December 04, 2025 at a share price of $1.42.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors
GlobeNewswire Inc.
Nov 05, 2025 12:30 PM GMT
HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and so
Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting
GlobeNewswire Inc.
Nov 03, 2025 2:15 PM GMT
Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associ
Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program
GlobeNewswire Inc.
Oct 06, 2025 11:30 AM GMT
Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell s